原发性肝细胞性肝癌血清学标志物的研究进展  

Progress in serological markers of primary hepatocellular carcinoma

作　　者：欧阳珂 周东辉[1] 李爽[1] OUYANG Ke;ZHOU Dong-hui;LI Shuang(Department of Infections Disease,The First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China)

机构地区：[1]南京医科大学第一附属医院感染科,南京210029

出　　处：《世界临床药物》2018年第8期569-573,共5页World Clinical Drug

基　　金：卫生部行业基金项目(编号:YWLKJJHKYJJ-Q2504)

摘　　要：肝细胞性肝癌(HCC)是全球最常见的恶性肿瘤之一,发病率居世界恶性肿瘤的第6位,病死率居第2位,早期诊断能提高HCC的5年生存率。HCC血清学标志物可以有效地筛查、诊断疾病状态,并监测治疗效果,具有经济、便捷、灵敏等特点。本文综述近年来HCC血清学标志物的最新进展,为HCC的诊断和治疗提供参考。Hepatocellular carcinoma（HCC） is one of the most common malignacies in the world. The incidence rate ranks sixth in the world for malignant tumors, and the mortality rate ranks second. Early diagnosis can increase the 5-year survival rate of HCC. However, the serological markers of HCC can effectively screen, diagnose the disease state, and monitor its treatment effect conveniently. It is economical, convenient and sensitive. This article reviews recent advances in HCC serological markers and provides a reference for HCC diagnosis and treatment.

关 键 词：肝细胞性肝癌(HCC) 血清学标志物 诊断 

分 类 号：R735.7[医药卫生—肿瘤]